586-IgG1 Plasma Cell Responses to Immune Checkpoint Blockade
This research highlights the essential role of humoral immunity in determining the success of immune checkpoint blockade (ICB) therapy across various cancers, particularly hepatocellular carcinoma. The study identifies that patients who respond well to treatment exhibit a significant expansion of IgG1-secreting plasma cells and specialized B cell niches within the tumor environment. These beneficial immune cells produce antibodies targeting cancer-testis antigens, a process that appears to coordinate with T cell activity to enhance anti-tumor responses. In contrast, non-responders tend to…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.